News

Respreeza® for Emphysema with A1-PI deficiency now Approved in European Union

CSL Behring, a global leader in the plasma protein therapeutics industry, has just announced its breakthrough maintenance treatment for patients with emphysema with documented severe A1-PI deficiency (AATD). Respreeza® has received marketing authorization in all states in the European Union (EU). Respreeza is a highly purified Alpha-1 protein derived from human plasma…

Screening For COPD in Asymptomatic Adults Not Recommended by USPSTF

Chronic Obstructive Pulmonary Disease (COPD) includes a group of progressive lung diseases such as emphysema, chronic bronchitis, non-reversible asthma, and some forms of bronchiectasis. COPD typically manifests itself in individuals who have had a long-term contact with harmful pollutants,a history of smoking, or who have a genetic predisposition to the disease. According to the…

Boehringer Releases Positive Update on OTEMTO Phase III Trial Findings Showing Superior Clinical Performance of Spiolto Respimat

Boehringer Ingelheim recently released a report on the company’s findings from the Phase IIIb OTEMTO 1 (NCT01964352) & 2 (NCT02006732) clinical trials, which are testing combination treatment Spiolto® Respimat® (tiotropium/olodaterol) for patients with chronic obstructive pulmonary disease (COPD). The update is published in the…

Entra Health Launches The Entra360 Platform

Entra Health has recently announced the launch of Entra360, a novel solution for easily and effectively implementing wireless biometric data. Entra360 is a particularly innovative solution for both the payer or provider, as well as the COPD clinical research market. Entra360 is one of several efforts the company is making to provide easy-to-implement solutions to allow remote…